NASDAQ · Biotechnology · USD
Crescent Biopharma, Inc. (CBIO) Stock Analysis
Crescent Biopharma, Inc. (CBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CBIO Key Statistics
As of Oct 21, 2026Trading
- Open
- $13.16
- Previous Close
- $13.07
- Day's Range
- 13.12–13.81
- 52-Week Range
- 8.72–27.41
- Volume
- 250.36K
Valuation
- Market Cap
- $467.31M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 39.33
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −7.63
Financials (FY)
- Revenue (FY)
- $10.84M
- Net Income (FY)
- −$153.94M
- Shares Outstanding
- 37.14M
- 1-Year Return
- +4.11%
Dividend and dates
- Avg Volume
- 402.25K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CBIO closed at $13.17, +4.11% over 1 year.
Crescent Biopharma, Inc. (CBIO) has a market capitalization of $467.31M.
CBIO Stock Return by Calendar Year
Crescent Biopharma, Inc. (CBIO) return since Sep 2022: what $10,000 became
- 1 year
- $10,000 $10,411
- +4.11%
- 3 years
- $10,000 $1,045
- −89.55%
- Since Sep 2022
- $10,000 $2,245
- −77.55%
If you had invested $10,000 in Crescent Biopharma, Inc. (CBIO) at the close on September 21, 2022, the earliest close on record here, it would have been worth $2,245 at the close on October 21, 2026: −77.55% in total, −30.65% a year, with dividends reinvested, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +11.05% |
| 2025 | −52.56% |
| 2024 | −89.41% |
| 2023 | −15.03% |
| 2022 (partial year) | +373.44% |
As of October 21, 2026.
CBIO Dividend History
Dividends per share, 2023 · 1 payments
| Year | Dividends per share | Payments | Change |
|---|---|---|---|
| 2023 | $24.00 | 1 | −83.2% |
| 2022 | $143.00 | 1 | — |
Most recent payment: $24.00 per share, ex-dividend January 13, 2023. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.
CBIO Valuation vs Biotechnology Median
Median of 608 stocks| Metric | CBIO | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 39.33 | 13.30 | 196% above |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
YahooCrescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial Data Expected In Q1 2027
BenzingaHC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target
BenzingaCrescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
YahooCrescent Biopharma Receives FDA Clearance For Its Investigational New Drug Application For CR-002 To Treat Advanced Solid Tumors
BenzingaCrescent Biopharma Announces Grants of Inducement Awards
Yahoo
All 12 articles ↓Show fewer ↑
The Nascent Crescent Biopharma Thesis: One Year Later And Things Are Steady
SeekingAlphaCrescent Biopharma, Inc. (CBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SeekingAlphaWedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target
BenzingaCrescent Biopharma to Present at September Investor Conferences
YahooWedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target
BenzingaCrescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B